

	<b>Drug</b>	<b>Mechanism of action</b>	<b>Notes</b>
Approved 6+	dupilumab	IL-4/IL-13 inhibitor via IL-4Ra	Ongoing trial for approval >6 months
Off-label for AD but approved in childhood	cyclosporine	calcineurin inhibitor via cyclophilin	Max dosing: 5mg/kg
	methotrexate	dihydrofolate reductase inhibitor	Not preferred due to slow onset and low efficacy but may still be useful if other options are not available
Trials ongoing	abrocitinib	Jak 1 inhibitor	
	lebrikizumab	IL-13 inhibitor	
	tralokinumab	IL-13 inhibitor	
	nemolizumab	IL31-R-A inhibitor	